Luzhu Biotechnology-B (02480.HK): Recombinant RSV vaccine approved for clinical trial in China

Zhito Finance APP News, Luzhu Biotech-B (02480.HK) announced that the recombinant respiratory syncytial virus (RSV) vaccine (recombinant RSV vaccine) developed by the Group has been approved by the National Medical Products Administration of the People's Republic of China (China) to conduct clinical trials in China.